Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study

Ghadami, Ladan; Hasibi, Mehrdad; Asadollahi–Amin, Ali; Asanjarani, Behzad; Farahmand, Mohammad; Abdollahi, Hamed

doi:10.1016/j.micpath.2022.105482

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…is analysis was in accordance with a recent report [40]. In terms of days to hospital discharge and rate of removal from the ventilator, a study evaluating the safety of convalescent plasma therapy based on acute coronavirus, in uenza, and Ebola virus infections found no bene t. is corresponds to the ndings of a similar study [41].…”

Section: Discussionsupporting

confidence: 89%

Efficacy and Safety of Convalescence Plasma Therapy in COVID-19 Patients: A Systematic Review and Meta-Analysis

Dai

Tang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. The coronavirus disease 2019 (COVID-19) has outbroken into a global pandemic. The death rate for hospital patients varied between 11% and 15%. Although COVID-19 is extremely contagious and has a high fatality rate, the amount of knowledge available in the published literature and public sources is rapidly growing. The efficacy of convalescent plasma (CP) therapy for COVID-19 is controversial. Objective. This meta-analysis was designed to assess the efficacy of CP therapy for COVID-19 through a literature survey. Methods. Until August 30, 2021, a literature search was undertaken in Pubmed, Embase, Web of Science, Cochrane Central Register of Controlling Trials (Central), and China National Knowledge Infrastructure databases. The Risk Ratio (RR) and 95% confidence intervals (CIs) were pooled using a fixed or random effect model in dichotomous data. Mean difference (MD) and 95% confidence intervals (CIs) were pooled using a fixed or random effect model in continuous data. Studies with missing or unsuitable data were presented descriptively in the outcomes. Results. In total, thirteen randomized controlled trials (RCTs) were selected for the present meta-analysis, which included a total of 13232 participants. Our results revealed that the CP group has lower mortality compared to the control group, and there was a statistically significant difference (RR: 0.70, 95% CI: 0.55, 0.89, Z = 2.92, P = 0.004 < 0.01 ); other secondary outcomes such as the shortness of breath symptom improved significantly in CP group (RR:1.48, 95% CI: 1.13, 1.93, Z = 2.85, P = 0.004 < 0.01 ), as well as Interleukin-6 (IL-6) (MD: −4.46, 95% CI: −8.28, −0.63, Z = 2.28, P = 0.02 < 0.05 ) and Ferritin (MD: −447.68, 95% CI: −501.75, −393.6, Z = 16.23, P < 0.00001 ) are reduced significantly in CP group. However, there was no statistically significant change in the ventilator withdrawal rate, imaging results improvement, or days to hospital discharge. There was also no substantial difference in viral nucleic acid negative conversion rate and neutralizing antibody-positive conversion rate, as well as the incidence of adverse reactions. Conclusions. The safety and potential efficacy of convalescent plasma therapy offer a promising treatment strategy for COVID-19. CP therapy can reduce mortality and improve breath and inflammatory cytokines IL-6 and Ferritin in COVID-19 with no significant increase in adverse reactions. However, it does not affect improving virology indicators. In summary, more high-quality clinical trials are needed to verify the conclusion of the present study.

show abstract

Section: Discussionsupporting

confidence: 89%

Efficacy and Safety of Convalescence Plasma Therapy in COVID-19 Patients: A Systematic Review and Meta-Analysis

Dai

Tang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…in fact, it was not possible to observe a decrease in the 30-day mortality rate. However, we believe that more studies are needed to evaluate the utility of convalescent plasma therapy, the selection criteria for patient selection needed to evaluate the efficacy of convalescent plasma therapy, the criteria for patient selection, the evaluation of the CCP title, the administration schedule deserve further consideration [46][47][48][49][50][51][52][53].…”

Section: Discussionmentioning

confidence: 99%

Convalescent Plasma Infusion does not Appear to Change the Prognosis in Italian Patients Hospitalized with Sars-Cov-2 Pneumonia

Gessoni¹,

Roveroni²,

Moro³

et al. 2023

IBRR

View full text Add to dashboard Cite

Aims: This case-control prospective study aimed to describe the effects of COVID convalescent plasma (CCP) on late mortality in hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia. Study Design: In this study were enrolled 214 consecutive patients with moderate to severe COVID-19 pneumonia hospitalized during the fourth trimester of 2020 in Venice Prefecture (North-East Italy). admitted to COVID-19 Hospitals of our district were enrolled. Methodology: Confirmation of SARS-CoV-2 infection was made through reverse transcription-polymerase chain reaction test in nasopharyngeal swabs. The severity of each patient’s clinical condition was determined considering the Berlin score radiological findings and ventilatory data. Clinical data, risk factors and comorbidity, laboratory test reports and imaging diagnosis of all patients were recorded at hospitalization. In Italy, during the fourth trimester 2020 standard therapy for COVID-19 Pneumonia was: NSAIDs, ventilator support, LMWH, steroids, antibiotics and antiviral drugs; 108 patients received standard therapy alone and 106 received standard therapy in combination with CCP. The endpoint was mortality at 30 days. Results: Patients series were comparable for gender, age, comorbidity and risk factors, Berlin score, PaO2/FiO2. Data concerning radiological findings and data concerning ventilatory support suggested a higher severity of patients treated with standard therapy plus CCP. Mortality rate at 30 days was 30.6% among subjects treated with standard therapy versus 30.2% among subjects treated with standard therapy plus CCP. The mortality observed in the two groups did not differ significantly. In the present study, however, we observed a higher mortality than reported in the literature. This result may be attributable to the greater severity of the patients considered. Conclusions: This case-control prospective study showed that in a cohort of hospitalized patients suffering from severe 19 pneumonia, the addition of CCP to the standard therapy did not impact the mortality rate at 30 days. However, we believe that further studies are needed to evaluate the effectiveness of convalescent plasma therapy.

show abstract

Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study

Cited by 2 publications

References 21 publications

Efficacy and Safety of Convalescence Plasma Therapy in COVID-19 Patients: A Systematic Review and Meta-Analysis

Efficacy and Safety of Convalescence Plasma Therapy in COVID-19 Patients: A Systematic Review and Meta-Analysis

Convalescent Plasma Infusion does not Appear to Change the Prognosis in Italian Patients Hospitalized with Sars-Cov-2 Pneumonia

Contact Info

Product

Resources

About